Olaf Stüve

Defining the clinical course of multiple sclerosis

Fred Lublin, Stephen C. Reingold, Jeffrey A. Cohen et al. · Neurology · 2014 · 3K citations · Full text

Neuroimaging Biomarkers, Scleroderma, Neurological Disease +15

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

Sawsan Youssef, Olaf Stüve, Juan C. Patarroyo et al. · Nature · 2002 · 1.1K citations

Inflammation, Autoimmune Disease, Disease Mechanism +13

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Type II monocytes modulate T cell–mediated central nervous system autoimmune disease

Martin S. Weber, Thomas Prod’homme, Sawsan Youssef et al. · Nature Medicine · 2007 · 445 citations

Immunology, Immune Regulation, Cd4 T Cell Responses +19

Immune surveillance in multiple sclerosis patients treated with natalizumab

Olaf Stüve, Christina M. Marra, Keith R. Jerome et al. · Annals of Neurology · 2006 · 434 citations · Full text